论文部分内容阅读
目的 :探讨恶性肿瘤 DNA倍体分类的临床生物学行为依据。方法 :用流式细胞术对 10 0例恶性肿瘤患者瘤组织进行了 DNA含量分析 ,并对不同倍体类型与各种临床生物学行为的关系进行了探讨。结果 :把瘤组织类型分为二倍体 (D)、近二倍体 (ND)、四倍体 (T)、非整倍体 (AN)、多异倍体 (M) ,后 4种倍体统称为 DNA异倍体 (H)。随临床分期、病理分级增加和转移的出现 ,D检出率越来越低 ,M检出率越来越高 ;肿瘤倍体从 D→ ND→ T→ AN→ M,其平均临床分期数和病理分级数均越来越高。结论 :倍体 D→ ND→ T→ AN→ M患者肿瘤恶性度逐渐升高。该结果为患者间临床生物学行为差异分析提供了生物学依据 ,也为肿瘤倍体分类提高了科学性。
Objective: To explore the clinical biological behavior basis of DNA ploidy classification in malignant tumors. Methods :The DNA content of tumor tissues from 100 patients with malignant tumors was analyzed by flow cytometry. The relationship between different ploidy types and various clinical biological behaviors was discussed. RESULTS: The tumor tissue types were divided into diploid (D), near diploid (ND), tetraploid (T), aneuploid (AN), and polyploid (M), and the latter 4 times. The body is collectively referred to as DNA aneuploid (H). With the increase of clinical stage, pathological grade, and metastasis, the detection rate of D is getting lower and lower, and the detection rate of M is getting higher and higher; the tumor ploidy is from D→ ND→ T→ AN→ M, and the average clinical stage number is The number of pathological grades is increasing. Conclusion : The ploidy D → ND → T → AN → M patients have gradually increased malignancy. This result provides a biological basis for the analysis of clinical biological behavior differences among patients, and also improves the scientificity of tumor ploidy classification.